

**INFORMING VACCINATION PROGRAMS:**  
**A Guide to the  
Design and Conduct  
of Dengue Serosurveys**

**Immunization, Vaccines and Biologicals**



**World Health  
Organization**

---

## Informing vaccination programs: a guide to the design and conduct of dengue serosurveys

ISBN 978-92-4-151258-9

© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** Informing vaccination programs: a guide to the design and conduct of dengue serosurveys. Geneva: World Health Organization; 2017.

Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in Geneva, Switzerland

---

# **INFORMING VACCINATION PROGRAMS: A Guide to the Design and Conduct of Dengue Serosurveys**

**Immunization, Vaccines and Biologicals**



**World Health  
Organization**



---

# Contents

Acknowledgements.....	ii
Abbreviations & acronyms .....	iii
<b>1. Introduction .....</b>	<b>1</b>
<b>2. Designing a dengue serosurvey .....</b>	<b>3</b>
2.1. Survey objectives.....	3
2.2. Age range to survey .....	4
2.3. Area to survey .....	5
2.4. Survey design.....	8
2.5. Sample size.....	12
2.6. Diagnostic assays and validation .....	15
2.7. Sources of bias .....	19
2.8. Examples of sampling procedures .....	20
2.9. Regression modeling.....	22
<b>3. Field and laboratory procedures .....</b>	<b>24</b>
3.1. Preparing for the field.....	24
3.2. Human resources .....	24
3.3. Data collection.....	25
3.4. Specimen collection and processing .....	26
3.5. Laboratory testing algorithm .....	27
3.6. Ethical considerations.....	28
<b>4. Survey analysis .....</b>	<b>29</b>
4.1. Descriptive epidemiology.....	29
4.2. Survey weights and design specification.....	30
4.3. Seroprevalence estimates .....	31
4.4. Regression modeling (optional) .....	31
4.5. Force of infection estimation (optional).....	32
4.6. Interpretation, report writing, and dissemination.....	33
References .....	34
Appendix 1. Glossary of terms.....	37
Appendix 2. Statistical appendix .....	39

---

---

# Acknowledgements

The guidance articulated in this document is based on discussions of an ad hoc WHO Technical Working Group on Dengue Serosurveys to Target Vaccination. This document was developed on behalf of WHO by **Natalie Dean** (University of Florida).

Special thanks are due to the numerous colleagues who contributed to the discussions and preparation of this document, including the following (in alphabetical order): **Katie Anderson** (University of Minnesota), **Brad Biggerstaff** (US Centers for Disease Control and Prevention), **Oliver Brady** (London School of Hygiene and Tropical Medicine), **Marcelo N. Burattini** (University of Sao Paolo), **Neil Ferguson** (Imperial College), **Emily Gurley** (ICDDR,B), **Elizabeth Hunsperger** (US Centers for Disease Control and Prevention), **Barbara Johnson** (US Centers for Disease Control and Prevention), **Natsuko Imai** (Imperial College), **Ira Longini** (University of Florida), **Mick Mulders** (WHO), **Minal Patel** (WHO), **Isabel Rodriguez** (Johns Hopkins School of Public Health), **Diana Rojas** (Red AEDES - Colombia, University of Florida), **Hasi-tha Tissera** (Sri Lanka Ministry of Health), **Kirsten Vannice** (WHO), and **In-Kyu Yoon** (International Vaccine Institute).

Input was also provided during a review by the WHO Immunization and vaccines related implementation research advisory committee (IVIR-AC). The meeting report and recommendations may be found at [http://www.who.int/immunization/research/committees/ivir\\_ac](http://www.who.int/immunization/research/committees/ivir_ac).

---

# Abbreviations & acronyms

AIC	Akaike information criterion
CHIKV	chikungunya virus
CI	confidence interval
CYD-TDV	Dengvaxia <sup>®</sup> vaccine
DEFF	design effect
DENV	dengue virus
E	envelope protein
ELISA	enzyme-linked immunosorbent assay
ESS	effective sample size
FN	false negative
FOI	force of infection
FP	false positive
HPV	human papillomavirus
ICC	intraclass/intracluster correlation coefficient
IgG	immunoglobulin G
IgM	immunoglobulin M
JE	Japanese encephalitis
NPV	negative predictive value
NS1	non-structural protein 1
NT	neutralization test
OD	optical density
PPS	probability proportional to size
PPV	positive predictive value
ROC	receiver operator curve
PRNT	plaque reduction neutralization test
SAGE	WHO Strategic Advisory Group of Experts

---

SOP	standard operating procedure
TdaP	tetanus, diphtheria, and pertussis
TN	true negative
TP	true positive
WHO	World Health Organization
WNV	West Nile virus
YF	yellow fever
ZIKV	Zika virus

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_24356](https://www.yunbaogao.cn/report/index/report?reportId=5_24356)

